*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach - as a primary procedure code | 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach - as a primary or secondary procedure code | |
|---|---|---|
| Total National Projected Hospitalizations - Annualized (Present on Admission - All) | 50,177 | 82,068 |
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | 32,067 | 58,959 |
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | ||
| Total Medicare Hospitalizations after Exclusion | ||
| Avg. LOS | ||
| Readmission Rate (%) | ||
| Unplanned Readmission Rate (%) | ||
| Total Medicare Payments | ||
| Payment Per Day | ||
| Payment Per Hospitalization | ||
| Total Medicare Charges | ||
| Avg. Charges | ||
| Mortality Rate (%) | ||
| SNF Discharge Rate (%) | ||
| Home Discharge Rate (%) |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 846: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 837: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 838: CHEMOTHERPY WITH ACUTE LEUKEMIA AS SDX WITH COMPLICATION OR COMORBIDITY (CC) OR HIGH DOSE CHEMOTHERAPY AGENT | DRG 839: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 45,065 | ||||
| Total Hospitalizations with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 15,831 | ||||
| DRG Share of Total Hospitalizations | 0.14 | ||||
| % of Total ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach in DRG | 49.37 | ||||
| Avg LOS at DRG | 4.03 | ||||
| Avg LOS with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 4.11 | ||||
| Readmission Rate at DRG | 66.75 | ||||
| Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 68.71 | ||||
| Unplanned Readmission Rate at DRG | 10.94 | ||||
| Unplanned Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 10.42 | ||||
| Total Medicare payments at DRG | $438,494,977 | ||||
| Total Medicare payments with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $161,052,948 | ||||
| Total Medicare payment per Day at DRG | $2,416 | ||||
| Total Medicare payment per Day with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $2,476 | ||||
| Total Medicare payment per Hospitalization at DRG | $9,730 | ||||
| Total Medicare payment per Hospitalization with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $10,173 | ||||
| Total Medicare Charges at DRG | $2,145,591,374 | ||||
| Total Medicare Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $753,314,873 | ||||
| Avg Charges at DRG | $47,611 | ||||
| Avg Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $47,585 | ||||
| Mortality Rate at DRG | 0.08 | ||||
| Mortality Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | NA | ||||
| SNF Discharge Rate at DRG | 4.35 | ||||
| SNF Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 4.42 | ||||
| Home Discharge Rate at DRG | 81.76 | ||||
| Home Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 81.58 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 840: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 834: ACUTE LEUKEMIA WITHOUT MAJOR O.R. PROCEDURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 841: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH COMPLICATION OR COMORBIDITY (CC) | DRG 848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 829: MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH OTHER O.R. PROCEDURE WITH COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 29,081 | ||||
| Total Hospitalizations with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 981 | ||||
| DRG Share of Total Hospitalizations | 0.09 | ||||
| % of Total ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach in DRG | 3.06 | ||||
| Avg LOS at DRG | 9.8 | ||||
| Avg LOS with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 15.54 | ||||
| Readmission Rate at DRG | 37.3 | ||||
| Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 48.61 | ||||
| Unplanned Readmission Rate at DRG | 22.57 | ||||
| Unplanned Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 21.52 | ||||
| Total Medicare payments at DRG | $683,745,757 | ||||
| Total Medicare payments with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $34,786,338 | ||||
| Total Medicare payment per Day at DRG | $2,399 | ||||
| Total Medicare payment per Day with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $2,281 | ||||
| Total Medicare payment per Hospitalization at DRG | $23,512 | ||||
| Total Medicare payment per Hospitalization with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $35,460 | ||||
| Total Medicare Charges at DRG | $3,049,100,784 | ||||
| Total Medicare Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $192,288,231 | ||||
| Avg Charges at DRG | $104,849 | ||||
| Avg Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $196,012 | ||||
| Mortality Rate at DRG | 13.07 | ||||
| Mortality Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 11.11 | ||||
| SNF Discharge Rate at DRG | 16.93 | ||||
| SNF Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 14.07 | ||||
| Home Discharge Rate at DRG | 29.4 | ||||
| Home Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 40.67 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 016: AUTOLOGOUS BONE MARROW TRANSPLANT WITH COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 842: LYMPHOMA AND NON-ACUTE LEUKEMIA WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 835: ACUTE LEUKEMIA WITHOUT MAJOR O.R. PROCEDURE WITH COMPLICATION OR COMORBIDITY (CC) | DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 57,175 | ||||
| Total Hospitalizations with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 222 | ||||
| DRG Share of Total Hospitalizations | 0.17 | ||||
| % of Total ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach in DRG | 0.69 | ||||
| Avg LOS at DRG | 6.45 | ||||
| Avg LOS with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 10.7 | ||||
| Readmission Rate at DRG | 26.69 | ||||
| Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 39.34 | ||||
| Unplanned Readmission Rate at DRG | 20.8 | ||||
| Unplanned Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 28.42 | ||||
| Total Medicare payments at DRG | $651,389,136 | ||||
| Total Medicare payments with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $2,915,059 | ||||
| Total Medicare payment per Day at DRG | $1,767 | ||||
| Total Medicare payment per Day with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $1,227 | ||||
| Total Medicare payment per Hospitalization at DRG | $11,393 | ||||
| Total Medicare payment per Hospitalization with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $13,131 | ||||
| Total Medicare Charges at DRG | $3,285,887,644 | ||||
| Total Medicare Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $22,803,501 | ||||
| Avg Charges at DRG | $57,471 | ||||
| Avg Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $102,718 | ||||
| Mortality Rate at DRG | 12.27 | ||||
| Mortality Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 13.96 | ||||
| SNF Discharge Rate at DRG | 12.94 | ||||
| SNF Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 13.96 | ||||
| Home Discharge Rate at DRG | 28.03 | ||||
| Home Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 29.73 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 181: RESPIRATORY NEOPLASMS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 375: DIGESTIVE MALIGNANCY WITH COMPLICATION OR COMORBIDITY (CC) | DRG 374: DIGESTIVE MALIGNANCY WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 435: MALIGNANCY OF HEPATOBILIARY SYSTEM OR PANCREAS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 436: MALIGNANCY OF HEPATOBILIARY SYSTEM OR PANCREAS WITH COMPLICATION OR COMORBIDITY (CC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 37,484 | ||||
| Total Hospitalizations with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 160 | ||||
| DRG Share of Total Hospitalizations | 0.11 | ||||
| % of Total ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach in DRG | 0.5 | ||||
| Avg LOS at DRG | 4.49 | ||||
| Avg LOS with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 6.33 | ||||
| Readmission Rate at DRG | 27.89 | ||||
| Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 37.42 | ||||
| Unplanned Readmission Rate at DRG | 21.07 | ||||
| Unplanned Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 28.39 | ||||
| Total Medicare payments at DRG | $287,773,529 | ||||
| Total Medicare payments with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $1,584,859 | ||||
| Total Medicare payment per Day at DRG | $1,709 | ||||
| Total Medicare payment per Day with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $1,565 | ||||
| Total Medicare payment per Hospitalization at DRG | $7,677 | ||||
| Total Medicare payment per Hospitalization with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $9,905 | ||||
| Total Medicare Charges at DRG | $1,483,578,942 | ||||
| Total Medicare Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $9,687,166 | ||||
| Avg Charges at DRG | $39,579 | ||||
| Avg Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $60,545 | ||||
| Mortality Rate at DRG | 4.3 | ||||
| Mortality Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | NA | ||||
| SNF Discharge Rate at DRG | 10.7 | ||||
| SNF Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 9.38 | ||||
| Home Discharge Rate at DRG | 44.82 | ||||
| Home Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 56.88 |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 1,469 |
| UCSF MEDICAL CENTER | 505 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 692 |
| MAYO CLINIC HOSPITAL - SAINT MARYS CAMPUS | 1216 2ND ST SW | ROCHESTER | MN | 55902 | 588 |
| MOFFITT CANCER CENTER | 12902 MAGNOLIA DR | TAMPA | FL | 33612 | |
| BARNES JEWISH HOSPITAL | 1 BARNES-JEWISH HOSPITAL PLZ | SAINT LOUIS | MO | 63110 | |
| UNIVERSITY OF WASHINGTON MEDICAL CENTER | 1959 NE PACIFIC ST | SEATTLE | WA | 98195 | |
| CITY OF HOPE DUARTE | 1500 E DUARTE RD | DUARTE | CA | 91010 | |
| STANFORD HEALTHCARE | 300 PASTEUR DR | STANFORD | CA | 94305 | |
| ARTHUR G JAMES CANCER HOSPITAL | 300 W 10TH AVE | COLUMBUS | OH | 43210 | |
| THE UNIVERSITY OF CHICAGO MEDICAL CENTER | 5841 S. MARYLAND AVE | CHICAGO | IL | 60637 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. NEEL KAMAL GUPTA | 1959 NE PACIFIC ST | SEATTLE | WA | 98195 | 102 |
| Dr. DAVID JOSEPH IBERRI | 300 PASTEUR DR | STANFORD | CA | 94305 | 93 |
| Dr. RUPA NARAYAN | 622 W 168TH ST # VC2-205 | NEW YORK | NY | 10032 | 92 |
| Dr. SHAGUN D ARORA | 401 S BALLENGER HWY | FLINT | MI | 48532 | |
| Dr. RONDEEP SINGH BRAR | 875 BLAKE WILBUR DR | PALO ALTO | CA | 94304 | |
| Dr. MELISSA LEIGH LARSON | 1725 W HARRISON ST | CHICAGO | IL | 60612 | |
| Dr. ZAHID IQBAL | 4501 X ST | SACRAMENTO | CA | 95817 | |
| Dr. LAUREN SHIZUE MAEDA | 300 PASTEUR DR | STANFORD | CA | 94305 | |
| Dr. TAMARA LEA MUSGRAVE | 172 S MAYO TRL | PIKEVILLE | KY | 41501 | |
| Dr. VIKAS BHUSHAN | 7777 FOREST LN | DALLAS | TX | 75230 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. MELISSA LEIGH LARSON | 1725 W HARRISON ST | CHICAGO | IL | 60612 | 106 |
| Dr. NEEL KAMAL GUPTA | 1959 NE PACIFIC ST | SEATTLE | WA | 98195 | 97 |
| Dr. RUPA NARAYAN | 622 W 168TH ST # VC2-205 | NEW YORK | NY | 10032 | 97 |
| Dr. DAVID JOSEPH IBERRI | 300 PASTEUR DR | STANFORD | CA | 94305 | |
| Dr. SHAGUN D ARORA | 401 S BALLENGER HWY | FLINT | MI | 48532 | |
| Dr. RONDEEP SINGH BRAR | 875 BLAKE WILBUR DR | PALO ALTO | CA | 94304 | |
| Dr. PARAMESWAREN VENUGOPAL | 1725 W HARRISON ST | CHICAGO | IL | 60612 | |
| Dr. LORI ANN LESLIE | 1515 HOLCOMBE BLVD, UNIT 463 | HOUSTON | TX | 77030 | |
| Dr. LAUREN SHIZUE MAEDA | 300 PASTEUR DR | STANFORD | CA | 94305 | |
| Dr. VIKAS BHUSHAN | 7777 FOREST LN | DALLAS | TX | 75230 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 846: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 016: AUTOLOGOUS BONE MARROW TRANSPLANT WITH COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 837: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 840: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 45,065 | ||||
| Total Hospitalizations with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 19,097 | ||||
| DRG Share of Total Hospitalizations | 0.14 | ||||
| % of Total ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach in DRG | 32.39 | ||||
| Avg LOS at DRG | 4.03 | ||||
| Avg LOS with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 4.23 | ||||
| Readmission Rate at DRG | 66.75 | ||||
| Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 68.96 | ||||
| Unplanned Readmission Rate at DRG | 10.94 | ||||
| Unplanned Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 10.85 | ||||
| Total Medicare payments at DRG | $438,494,977 | ||||
| Total Medicare payments with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $197,601,351 | ||||
| Total Medicare payment per Day at DRG | $2,416 | ||||
| Total Medicare payment per Day with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $2,449 | ||||
| Total Medicare payment per Hospitalization at DRG | $9,730 | ||||
| Total Medicare payment per Hospitalization with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $10,347 | ||||
| Total Medicare Charges at DRG | $2,145,591,374 | ||||
| Total Medicare Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $959,333,256 | ||||
| Avg Charges at DRG | $47,611 | ||||
| Avg Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $50,235 | ||||
| Mortality Rate at DRG | 0.08 | ||||
| Mortality Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 0.06 | ||||
| SNF Discharge Rate at DRG | 4.35 | ||||
| SNF Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 4.42 | ||||
| Home Discharge Rate at DRG | 81.76 | ||||
| Home Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 81.39 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 834: ACUTE LEUKEMIA WITHOUT MAJOR O.R. PROCEDURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 014: ALLOGENEIC BONE MARROW TRANSPLANT | DRG 838: CHEMOTHERPY WITH ACUTE LEUKEMIA AS SDX WITH COMPLICATION OR COMORBIDITY (CC) OR HIGH DOSE CHEMOTHERAPY AGENT | DRG 841: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH COMPLICATION OR COMORBIDITY (CC) | DRG 839: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 12,641 | ||||
| Total Hospitalizations with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 2,722 | ||||
| DRG Share of Total Hospitalizations | 0.04 | ||||
| % of Total ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach in DRG | 4.62 | ||||
| Avg LOS at DRG | 16.42 | ||||
| Avg LOS with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 27.26 | ||||
| Readmission Rate at DRG | 41.54 | ||||
| Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 52.07 | ||||
| Unplanned Readmission Rate at DRG | 17.96 | ||||
| Unplanned Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 16.28 | ||||
| Total Medicare payments at DRG | $591,889,384 | ||||
| Total Medicare payments with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $169,886,531 | ||||
| Total Medicare payment per Day at DRG | $2,852 | ||||
| Total Medicare payment per Day with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $2,290 | ||||
| Total Medicare payment per Hospitalization at DRG | $46,823 | ||||
| Total Medicare payment per Hospitalization with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $62,412 | ||||
| Total Medicare Charges at DRG | $2,437,161,576 | ||||
| Total Medicare Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $895,128,906 | ||||
| Avg Charges at DRG | $192,798 | ||||
| Avg Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $328,850 | ||||
| Mortality Rate at DRG | 21.77 | ||||
| Mortality Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 16.24 | ||||
| SNF Discharge Rate at DRG | 6.6 | ||||
| SNF Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 6.83 | ||||
| Home Discharge Rate at DRG | 30.51 | ||||
| Home Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 42.47 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 823: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER O.R. PROCEDURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 829: MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH OTHER O.R. PROCEDURE WITH COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 835: ACUTE LEUKEMIA WITHOUT MAJOR O.R. PROCEDURE WITH COMPLICATION OR COMORBIDITY (CC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 7,258 | ||||
| Total Hospitalizations with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 871 | ||||
| DRG Share of Total Hospitalizations | 0.02 | ||||
| % of Total ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach in DRG | 1.48 | ||||
| Avg LOS at DRG | 13.76 | ||||
| Avg LOS with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 21.64 | ||||
| Readmission Rate at DRG | 39.67 | ||||
| Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 48.37 | ||||
| Unplanned Readmission Rate at DRG | 23.8 | ||||
| Unplanned Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 24.32 | ||||
| Total Medicare payments at DRG | $256,092,605 | ||||
| Total Medicare payments with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $40,160,500 | ||||
| Total Medicare payment per Day at DRG | $2,565 | ||||
| Total Medicare payment per Day with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $2,131 | ||||
| Total Medicare payment per Hospitalization at DRG | $35,284 | ||||
| Total Medicare payment per Hospitalization with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $46,108 | ||||
| Total Medicare Charges at DRG | $1,187,005,134 | ||||
| Total Medicare Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $231,702,159 | ||||
| Avg Charges at DRG | $163,544 | ||||
| Avg Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $266,019 | ||||
| Mortality Rate at DRG | 12.83 | ||||
| Mortality Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 13.55 | ||||
| SNF Discharge Rate at DRG | 19.77 | ||||
| SNF Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 21.47 | ||||
| Home Discharge Rate at DRG | 29.75 | ||||
| Home Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 30.54 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 374: DIGESTIVE MALIGNANCY WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 375: DIGESTIVE MALIGNANCY WITH COMPLICATION OR COMORBIDITY (CC) | DRG 842: LYMPHOMA AND NON-ACUTE LEUKEMIA WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 181: RESPIRATORY NEOPLASMS WITH COMPLICATION OR COMORBIDITY (CC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 32,646 | ||||
| Total Hospitalizations with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 531 | ||||
| DRG Share of Total Hospitalizations | 0.1 | ||||
| % of Total ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach in DRG | 0.9 | ||||
| Avg LOS at DRG | 7.59 | ||||
| Avg LOS with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 17.15 | ||||
| Readmission Rate at DRG | 28.12 | ||||
| Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 43.85 | ||||
| Unplanned Readmission Rate at DRG | 19.5 | ||||
| Unplanned Readmission Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 26.62 | ||||
| Total Medicare payments at DRG | $468,044,879 | ||||
| Total Medicare payments with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $11,752,196 | ||||
| Total Medicare payment per Day at DRG | $1,889 | ||||
| Total Medicare payment per Day with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $1,291 | ||||
| Total Medicare payment per Hospitalization at DRG | $14,337 | ||||
| Total Medicare payment per Hospitalization with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $22,132 | ||||
| Total Medicare Charges at DRG | $2,155,025,187 | ||||
| Total Medicare Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $79,310,432 | ||||
| Avg Charges at DRG | $66,012 | ||||
| Avg Charges with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | $149,361 | ||||
| Mortality Rate at DRG | 11.79 | ||||
| Mortality Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 12.05 | ||||
| SNF Discharge Rate at DRG | 13.92 | ||||
| SNF Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 19.02 | ||||
| Home Discharge Rate at DRG | 26.98 | ||||
| Home Discharge Rate with ICD 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | 23.54 |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 2,947 |
| ARTHUR G JAMES CANCER HOSPITAL | 300 W 10TH AVE | COLUMBUS | OH | 43210 | 986 |
| UCSF MEDICAL CENTER | 505 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 958 |
| THE UNIVERSITY OF CHICAGO MEDICAL CENTER | 5841 S. MARYLAND AVE | CHICAGO | IL | 60637 | |
| BARNES JEWISH HOSPITAL | 1 BARNES-JEWISH HOSPITAL PLZ | SAINT LOUIS | MO | 63110 | |
| CITY OF HOPE DUARTE | 1500 E DUARTE RD | DUARTE | CA | 91010 | |
| MAYO CLINIC HOSPITAL - SAINT MARYS CAMPUS | 1216 2ND ST SW | ROCHESTER | MN | 55902 | |
| MOFFITT CANCER CENTER | 12902 MAGNOLIA DR | TAMPA | FL | 33612 | |
| STANFORD HEALTHCARE | 300 PASTEUR DR | STANFORD | CA | 94305 | |
| UNIVERSITY OF WASHINGTON MEDICAL CENTER | 1959 NE PACIFIC ST | SEATTLE | WA | 98195 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. DANIEL J HARAF | 5841 S MARYLAND AVE # MC1099 | CHICAGO | IL | 60637 | 125 |
| Dr. NEEL KAMAL GUPTA | 1959 NE PACIFIC ST | SEATTLE | WA | 98195 | 116 |
| Dr. RUPA NARAYAN | 622 W 168TH ST # VC2-205 | NEW YORK | NY | 10032 | 114 |
| Dr. JAYESH MEHTA | 675 N SAINT CLAIR ST | CHICAGO | IL | 60611 | |
| Dr. DAVID JOSEPH IBERRI | 300 PASTEUR DR | STANFORD | CA | 94305 | |
| Dr. RONDEEP SINGH BRAR | 875 BLAKE WILBUR DR | PALO ALTO | CA | 94304 | |
| Dr. SHAGUN D ARORA | 401 S BALLENGER HWY | FLINT | MI | 48532 | |
| Dr. HUN JU LEE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | |
| Dr. NATHAN H. FOWLER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | |
| Dr. VIKAS BHUSHAN | 7777 FOREST LN | DALLAS | TX | 75230 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. MELISSA LEIGH LARSON | 1725 W HARRISON ST | CHICAGO | IL | 60612 | 134 |
| Dr. RUPA NARAYAN | 622 W 168TH ST # VC2-205 | NEW YORK | NY | 10032 | 127 |
| Dr. DAVID JOSEPH IBERRI | 300 PASTEUR DR | STANFORD | CA | 94305 | 119 |
| Dr. HUN JU LEE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | |
| Dr. NEEL KAMAL GUPTA | 1959 NE PACIFIC ST | SEATTLE | WA | 98195 | |
| Dr. SHAGUN D ARORA | 401 S BALLENGER HWY | FLINT | MI | 48532 | |
| Dr. VIKAS BHUSHAN | 7777 FOREST LN | DALLAS | TX | 75230 | |
| Dr. ZAHID IQBAL | 4501 X ST | SACRAMENTO | CA | 95817 | |
| Dr. JAYESH MEHTA | 675 N SAINT CLAIR ST | CHICAGO | IL | 60611 | |
| Dr. RONDEEP SINGH BRAR | 875 BLAKE WILBUR DR | PALO ALTO | CA | 94304 |